NCT07667829Recruiting
Vasopressor Agents in Pulmonary Hypertension Crisis
Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 12 Jun 2026
- Start date
- 19 Aug 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- China National Center for Cardiovascular Diseases
- NCT number
- NCT07667829
What you commit to
- Study type: Interventional
- Planned participants: 75
- From 19 Aug 2026 to the primary completion date, 31 Dec 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);
- Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.
Other illness
- Hypersensitivity to the study drug;
Other
- At SCAI stage D or stage E ;
- Patients who only receive a diagnosis but no treatment in the hospital;
- Uncontrolled hyperthyroidism;
- Complicated with angle-closure glaucoma;
- Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;
- Pregnancy;
Who the study is looking for
- Age \> 18 years old;
- Signed informed consent form;
- Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH);
- Presenting with manifestations of pulmonary hypertensive crisis;
- Receiving both diagnosis and treatment in-hospital;
- No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese Academy of Medical Sciences, Fuwai Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Guangdong Provincial People's Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Not yet recruiting |
| Zhongnan Hospital of Wuhan University Coordinator of this site? Confirm its status | Wuhan | China | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.